Evommune, Inc. (EVMN)
NYQ · Healthcare · Biotechnology
$19.83
-4.16%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$714.2M
Shares Outstanding
36.0M
P/S (TTM)
71.4x
Exchange
NYQ
Currency
USD
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Quarterly Financials
| Metric | 2024-12-31 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 10.0M | 0.00 | 0.00 |
| Operating Income | -21.5M | -13.3M | -29.7M | -24.0M |
| Net Income | -20.7M | -12.5M | -28.3M | -21.7M |
| Diluted EPS | $nan | $-0.41 | $-1.43 | $-0.64 |
Annual Financials
| Metric | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Revenue | 13.0M | |
| Operating Income | -81.1M | |
| Net Income | -68.9M | |
| Diluted EPS | $-4.27 | $nan |